BRAF and melanoma: Dual inhibitor therapies have been successfully tested in malignant melanoma, where combining BRAF inhibitor (BRAFi) treatment with MEK inhibition (MEKi), improved PFS relative to those treated with BRAFi monotherapy [11] and similarly in colorectal cancer adding EGFR inhibitors (EGFRi) to BRAFi [12, 13].